Evaluation of Potential Allergenicity of New Soybean Varieties

Inclusion Criteria: * Age 6 months to 40 years of any sex and any race * A convincing history of allergic reaction to soybean and a positive ImmunoCAP (\>0.35 kU/L) and/or a positive skin prick test to soy. Subjects should have ImmunoCAP repeated (if not done within the last 6 months) at National Jewish Health. * One of the following: A) Recent (within one year) failed open OFC B) Positive DBPCFC to soy at NJH; or C) Recent (within one year) exposure to soybean resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing). * Written informed consent from parent/guardian and assent (when age appropriate). * Willingness to submit specimen for laboratory serum IgE testing * Willingness to submit lab specimen for ELISA testing Exclusion Criteria: * Inability to discontinue antihistamines for skin prick testing and OFCs * Current allergy to placebo ingredient (oat flour) OR reaction to any dose of placebo at the qualifying OFC * FEV1 value \<80% predicted or any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma severity (Step 3 or above), and greater than high daily doses of inhaled corticosteroids, as defined by the 2007 NHLBI guidelines inhaled corticosteroid dosing table (500 μg fluticasone or equivalents for an adult) * Asthma requiring either: \> 1 hospitalization in the past year for asthma or \> 1 ER visit in the past 6 months for asthma * History of intubation due to allergies or asthma * Life-threatening allergic reaction (i.e. respiratory compromise, hypoxia, hypotension) to food(s) within last 1 year * Diagnosis of active eosinophilic gastrointestinal disease in the past year * Severe or poorly controlled atopic dermatitis * Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual), immunomodulatory therapy (not including corticosteroids), or biologic therapy within the past year * Uncontrolled hypertension * Any use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers * Other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders), which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions * Pregnancy